Wen Zhang

Wen Zhang


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2019 in Clinical Science
Verified
Journal Article
Closed access
PDF file
JYJiaze Yu
Jiaze Yu
MYMinjie Yang
Minjie Yang
BZBo Zhou
Bo Zhou
JLJianjun Luo
Jianjun Luo
ZZZihan Zhang
Zihan Zhang
ZYZhiping Yan
Zhiping Yan
Accumulating evidences indicate that circular RNAs (circRNAs) play a vital role in diverse cancer biology. However, the contributions of circRNAs to hepatocellular carcinoma (HCC) and their underlying mechanism remain largely unknown. The present study aims at investigating the role of circRNA-104718 in HCC progression, which has been observed to be significantly up-regulated in HCC tissues. We found that, higher expression of circRNA-104718 also leds to a poor prognosis in HCC patients. Using luciferase binding assays and RNA immunoprecipitation studies, we identified circRNA-104718 is physically associated and co-expressed with microRNA (miR)-218-5p in HCC. Mechanistically, we demonstrated that circRNA-104718 functions as a competing endogenous RNAs (ceRNAs) and competes with thioredoxin domain-containing protein 5 (TXNDC5) mRNA and directly binds to miR-218-5p. Functionally, we found that ectopically expressed circRNA-104718 accelerated cell proliferation, migration, invasion, and inhibited apoptosis. In vivo studies on a nude mice model showed that circRNA-104718 overexpression could increase the tumor size and the rate of metastasis. Silencing of circRNA-104718 could decrease both the tumor size and metastasis significantly. Conversely, we also observed overexpression of miR-218-5p could in turn decrease the proliferation, migration, invasion, and increase apoptosis. Furthermore, circRNA-104718 could relieve the suppression of miR-218-5p target TXNDC5 and thereby cause an inhibition of miR’s functions. In summary, our results indicate that circRNA-104718 acts as a ceRNA and promotes HCC progression through the targeting of miR-218-5p/TXNDC5 signaling pathway. Thus, we propose that circRNA-104718 would be a promising target for HCC diagnosis and therapy.

13 August 2021 in Journal of Interventional Medicine
Verified
Journal Article
Open access
ZZZhiyuan Zheng
Zhiyuan Zheng
ZZZhiquan Zhuang
Zhiquan Zhuang
MYMinjie Yang
Minjie Yang
JLJianjun Luo
Jianjun Luo
WZWen Zhang
Wen Zhang
XWXiaolin Wang
Xiaolin Wang
To assess the safety and efficacy of bronchial artery embolization (BAE) for hemoptysis. Databases with articles published in English, including Pubmed, Embase, Web of science and Chochrane library, were comprehensively searched to get accurate, up-to-date and sufficient literature about BAE for hemoptysis until March 2020. The technical success rates, immediate control rates, recurrence rates, mortality rates, and total complication rates (minor and major complication rates) extracted from the articles were pooled to estimate and assess the efficacy and safety of BAE using random-effect and fixed-effect models. 21 articles published between 2008 and 2019, which include a total of 2511 patients, were studied to evaluate the safety and efficacy of BAE. The technical success and immediate control rates are 99.9% (95%CI: 99%–100%) and 99.5% (95%CI: 97.8%–99.2%), respectively. This study showed hemoptysis recurrence in 23.7% (95%CI: 18.5%–28.9%) with a mortality rate of 2% (95%CI: 0–3%). Additionally, the assessment of complications revealed a total complication rate of 13.4% (95% CI: 7.6–19.2%), in which 0.2% (95% CI: 0.2–0.4%) were major complications and 10% (95% CI: 4.7–9.6%) were minor complications. BAE is an effective, safe, and feasible procedure with a low complication rate for hemoptysis patients. However, recurrence of hemoptysis is still at high risk after BAE due to different underlying diseases.

22 April 2019 in BioMed Research International
Verified
Journal Article
Open access
PDF file
NDNan Du
Nan Du
JMJing-Qin Ma
Jing-Qin Ma
JLJian-Jun Luo
Jian-Jun Luo
QLQing-Xin Liu
Qing-Xin Liu
ZZZi-Han Zhang
Zi-Han Zhang
ZYZhiping Yan
Zhiping Yan
Purpose. The aim of this study was to evaluate the safety and efficacy of transcatheter arterial embolization (TAE) in patients with renal hemorrhage after percutaneous nephrolithotomy (PCNL) and evaluate the risk factors that may result in severe bleeding requiring TAE. Methods. We retrospectively reviewed 121 patients with post-PCNL renal hemorrhage. Thirty-two patients receiving endovascular embolization were compared with 89 patients only receiving conservative treatment. The demographic and clinical data were recorded and compared between the two groups. The values of estimated glomerular filtration rate (eGFR) and serum creatinine (SCr) were recorded preoperatively, postoperatively, and at last follow-up and analyzed to evaluate the safety and efficiency of TAE. Results. The successful hemostasis rate of conservative therapy was 73.6% (89/121) and that of TAE was 100% (32/32). SCr and eGFR were not significantly different before PCNL and after the last follow-up of TAE (SCr: 0.95 vs. 0.95 mg/dl, P=0.857; eGFR: 86.77 vs. 86.18 ml/min/1.73m2, P=0.715). The univariate analysis demonstrated that advanced age, urinary tract infection, and diabetes mellitus were significantly associated with severe bleeding during PCNL. Multivariate analysis further identified that diabetes mellitus was an independent risk factor for severe bleeding needing TAE [odds ratio (OR): 3.778, 95% confidence interval (CI):1.276-11.190, and P=0.016]. Conclusion. TAE is a safe and effective procedure to treat renal hemorrhage that cannot be resisted by conservative treatment after PCNL. Diabetes mellitus was associated with high risks of severe bleeding needing TAE after PCNL.

2 July 2025 in International Journal of Surgery
Verified
Journal Article
Open access
JWJuncheng Mbbs Wan
Juncheng Mbbs Wan
BTBufu Tang
Bufu Tang
WZWen Zhang
Wen Zhang
YZYongjie Zhou
Yongjie Zhou
CJChaoqiao Mbbs Jin
Chaoqiao Mbbs Jin
XQXudong Qu
Xudong Qu
Background: Hepatocellular carcinoma (HCC) remains a leading cause of cancer mortality. Emerging evidence suggests that quadruple therapy – combining hepatic artery infusion chemotherapy (HAIC), transcatheter arterial chemoembolization (TACE), targeted therapy, and immunotherapy – improves outcomes. However, few studies have directly compared this regimen with triple therapy (TACE plus targeted therapy and immunotherapy), and the optimal sequence of locoregional treatments within this regimen remains unclear. Objective: To compare the efficacy and safety of HAIC-first quadruple therapy, TACE-first quadruple therapy, and triple therapy in patients with unresectable HCC (uHCC). Materials and Methods: We retrospectively analyzed 158 patients with uHCC who received: HAIC-first quadruple therapy (HTTI, n = 61), TACE-first quadruple therapy (THTI, n = 41), or triple therapy (TTI, n = 56). Tumor response was assessed with modified RECIST; progression-free survival (PFS), overall survival (OS), and safety were compared. Results: The HTTI group achieved the highest objective response rate (ORR, 81.97%) and disease control rate (DCR, 96.72%), outperforming the THTI (ORR 73.17%, DCR 95.12%) and TTI groups (ORR 64.28%, DCR 85.71%). The median OS (mOS) was not reached in the HTTI group; the THTI group had a longer mOS (22.30 months) than the TTI group (19.00 months, P = 0.046). The median PFS (mPFS) was also longer in the HTTI group (12.90 months), compared to the THTI (10.40 months, P = 0.042) group and TTI groups (9.30 months, P < 0.001). Quadruple therapy increased grade 1 and 2 hypoalbuminemia, thrombocytopenia, and hand-foot syndrome, but grade 3 and 4 toxicities were similar across groups. Conclusion: Quadruple therapy demonstrates superior efficacy compared to triple therapy for uHCC. Initiating treatment with HAIC followed by TACE appears more effective than the reverse sequence and merits prospective validation.

18 September 2025 in Hepatology International
Verified
Journal Article
Open access
PDF file
YZYongjie Zhou
Yongjie Zhou
JMJingqin Ma
Jingqin Ma
YLYaozu Liu
Yaozu Liu
LMLi Ma
Li Ma
JYJiaze Yu
Jiaze Yu
JLJianjun Luo
Jianjun Luo
Background and aim The effect of shunting the left or right branch of the portal vein on the post-transjugular intrahepatic portosystemic shunt (TIPS) hepatic encephalopathy (HE) remains controversial. Therefore, we designed this prospective, randomized, single-blinded trial to compare the incidence of HE after shunting the left or right branch of the portal vein during TIPS in cirrhotic patients to prevent variceal rebleeding. Methods Consecutive patients diagnosed with hepatitis B virus (HBV)-related cirrhosis were randomly assigned in a 1:1 ratio to undergo the TIPS procedure, with the shunt directed to either the left or right branch of the portal vein. The primary outcome was the incidence of overt HE within 2 years. The secondary outcomes included shunt dysfunction, variceal rebleeding, survival, adverse events, and changes in liver function. Results Between June 2019 and December 2020, 130 patients were randomly divided into two groups (left branch group vs right branch group). The 2-year cumulative incidence rates of free overt HE in the left branch group did not demonstrate statistical superiority over the right branch group (78.5% vs 68.6%, respectively; p = 0.236, HR = 1.49, 95% CI 0.76–2.93). Similarly, no statistical differences were observed in stent patency, all-cause bleeding, survival, or adverse events. Conclusion Compared to shunting the right branch of the portal vein, shunting the left branch during TIPS placement did not impact the incidence of post-TIPS HE and other clinical outcomes in cirrhotic patients to prevent variceal rebleeding. The choice of puncture site should be primarily guided by the patient’s liver anatomy and the operator’s experience.

9 March 2022 in Cancer Cell International
Verified
Journal Article
Open access
PDF file
YJYu Jiaze
Yu Jiaze
HSHou Sinan
Hou Sinan
YMYang Minjie
Yang Minjie
ZYZhou Yongjie
Zhou Yongjie
DNDu Nan
Du Nan
ZYZhiping Yan
Zhiping Yan
Background: RNA 3’-terminal phosphate cyclase-like protein (Rcl1) is involved in pre-rRNA processing, but its implication in cancers remains unclear. Methods: RCL1 expressions in 21 malignancies was examinated through GEPIA website portal. Clinical implication data related to RCL1 level in Hepatocellular Carcinoma (HCC) samples were downloaded through TCGA, ICGC, GEO databases. Survival analysis and gene function enrichment analyses were performed through R software. The correlation between RCL1 expression and tumor immune infiltration was assessed via the TIMER2.0 database. The effects of Rcl1 overexpression or knockdown on cell growth and metastasis was evaluated by CCK8, transwell, and cell cycle assays. Results: RCL1 expression is commonly down-regulated in HCC. The lower expression of RCL1 is associated with higher tumor stage, higher AFP level, vascular invasion, and poor prognosis. RCL1 expression has a significant correlation with immune cells infiltration in HCC, especially myeloid-derived suppressor cell (MDSC). Moreover, it was further identified that Rcl1 expression was reduced in HCC cell lines and negatively correlated with invasion of HCC cell lines. Immunofluorescence (IF) analysis revealed that the level of Rcl1 expression in the cytoplasm of HCC cells is significantly lower than that in the cytoplasm of L-02 cell. Moreover, both gain- and loss-of-function studies demonstrated that Rcl1 inhibited the growth and metastasis of HCC cells and regulated cell cycle progression in vitro. Conclusions: Rcl1 may serve as a novel tumor suppressor in HCC, and its biological effect needs further study.